After FibroGen's FDA rejection in anemia, Akebia CEO aims to seize first-in-class opening with ...

Retrieved on: 2021-08-16 14:37:30

Tags for this article:

Click the tags to see associated articles and topics

After FibroGen's FDA rejection in anemia, Akebia CEO aims to seize first-in-class opening with .... View article details on hiswai:

Excerpt

After AstraZeneca and FibroGen's roxadustat was rejected at the FDA, Akebia Therapeutics' rival drug vadadustat is hoping to be the first in the ...

Article found on: www.fiercepharma.com